Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.

@article{Safra2007EfficacyAT,
  title={Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.},
  author={Tamar Safra and Joseph Menczer and Rinat Molho Bernstein and Shulem Shpigel and Moshe Josef Inbar and Dan A Grisaru and Abraham Golan and Tally Levy},
  journal={Gynecologic oncology},
  year={2007},
  volume={105 1},
  pages={205-10}
}
OBJECTIVES We assessed the efficacy and toxicity of once-weekly topotecan (Hycamtin; GlaxoSmithKline) for relapsed or persistent epithelial ovarian cancer (EOC) and primary peritoneal carcinoma (PPC). METHODS Patients with recurrent or persistent EOC and PPC previously treated with > or = 1 course of platinum-based chemotherapy were treated with weekly topotecan 4.0 mg/m2 on days 1, 8, and 15 of a 28-day cycle in this prospective open-label, single-arm, phase II study. RESULTS The median… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…